These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 18171381)

  • 21. [Primary stabbing headache: clinical characteristics and response to treatment in a series of 67 patients].
    Pedraza MI; Guerrero-Peral ÁL; Herrero-Velázquez S; Mulero P; Barón J; Ruiz M; Marco-Llorente J; Fernández-Buey MN
    Rev Neurol; 2012 Oct; 55(8):469-74. PubMed ID: 23055428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of NF-κB and PCNA in the regulatory pathways of apoptosis by cyclooxygenase-2 inhibitors in experimental lung cancer.
    Setia S; Sanyal SN
    Mol Cell Biochem; 2012 Oct; 369(1-2):75-86. PubMed ID: 22752388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversible cerebral vasoconstriction syndrome possibly induced by etoricoxib.
    Dallocchio C; Arbasino C; Borutti G; Gola G; Egitto MG
    Clin Neuropharmacol; 2014; 37(5):154-7. PubMed ID: 25229174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relapsing remitting hypnic headache responsive to indomethacin in an adolescent: a case report.
    Prakash S; Dabhi AS
    J Headache Pain; 2008 Dec; 9(6):393-5. PubMed ID: 18825303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance.
    Asero R
    Clin Exp Dermatol; 2007 Nov; 32(6):661-3. PubMed ID: 17953635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.
    Vogt L; de Zeeuw D; Woittiez AJ; Navis G
    Nephrol Dial Transplant; 2009 Apr; 24(4):1182-9. PubMed ID: 19037084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
    Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
    J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
    Rubin BR; Burton R; Navarra S; Antigua J; Londoño J; Pryhuber KG; Lund M; Chen E; Najarian DK; Petruschke RA; Ozturk ZE; Geba GP
    Arthritis Rheum; 2004 Feb; 50(2):598-606. PubMed ID: 14872504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypnic headache: another indomethacin-responsive headache syndrome?
    Dodick DW; Jones JM; Capobianco DJ
    Headache; 2000; 40(10):830-5. PubMed ID: 11135028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bullous fixed drug eruption to etoricoxib--further evidence of intraepidermal CD8+ T cell involvement.
    Duarte AF; Correia O; Azevedo R; do Carmo Palmares M; Delgado L
    Eur J Dermatol; 2010; 20(2):236-8. PubMed ID: 20110201
    [No Abstract]   [Full Text] [Related]  

  • 33. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
    Nettis E; Colanardi MC; Ferrannini A; Vacca A; Tursi A
    Ann Allergy Asthma Immunol; 2005 Nov; 95(5):438-42. PubMed ID: 16312166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
    Meechan J
    Br J Oral Maxillofac Surg; 2006 Apr; 44(2):163-5. PubMed ID: 16191457
    [No Abstract]   [Full Text] [Related]  

  • 35. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Am J Gastroenterol; 2006 Feb; 101(2):311-7. PubMed ID: 16454836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 37. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taste masking of Etoricoxib by using ion-exchange resin.
    Patra S; Samantaray R; Pattnaik S; Barik BB
    Pharm Dev Technol; 2010; 15(5):511-7. PubMed ID: 19845450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on hemicrania continua.
    Cittadini E; Goadsby PJ
    Curr Pain Headache Rep; 2011 Feb; 15(1):51-6. PubMed ID: 21080113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
    Schwartz JI; Thach C; Lasseter KC; Miller J; Hreniuk D; Hilliard DA; Snyder KM; Gertz BJ; Gottesdiener KM
    J Clin Pharmacol; 2007 Dec; 47(12):1521-31. PubMed ID: 17925592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.